financial estimates
Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.
Telix Pharmaceuticals Acquires Early-Stage Assets From ImaginAb, Shares Late-Stage Pipeline Updates
Premium
The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both diagnostically and therapeutically.
Gilead has high hopes that anito-cel, a multiple myeloma cell therapy it is developing with Arcellx, can bolster its cell therapy franchise.
Myriad Genetics Enters Collaborations to Study MRD, Announces Preliminary Q3 Revenue Estimates
The company is studying the use of its Precise MRD test in the breast cancer setting. It also said it estimates between $210 million and $212 million in Q3 revenue.
The radioligand therapy hit roadblocks with supply constraints in early 2023, but a new manufacturing facility has since helped Novartis get back on track.